Table 1.
Baseline demographic and clinical characteristics of the study cohort (n=123)
| Baseline characteristics | Summary statistics, mean±SD or n (%) |
|---|---|
| Demographics | |
| Mean age (years) | 29.7±12.8 |
| Age categories (years) | |
| 0-18 | 24 (19.5) |
| 18-40 | 73 (59.3) |
| 40-60 | 26 (21.1) |
| Female gender | 61 (49.6) |
| Saudi nationality | 97 (78.9) |
| Smoking | 25 (20.3) |
| Family history of IBD | 16 (10.6) |
| Diagnosis | |
| Crohn’s disease | 70 (56.9) |
| Ulcerative colitis | 53 (43.1) |
| Disease location (CD) | |
| L1: Terminal ileal | 5 (7.1) |
| L2: Colonic | 40 (57.1) |
| L3: Ileo-colonic | 25 (35.7) |
| Disease behavior (CD) | |
| B1: Nonstricturing, nonpenetrating | 47 (67.1) |
| B2: Stricturing | 7 (10) |
| B3: Penetrating | 16 (22.9) |
| Perianal disease | 15 (11.2) |
| Disease extension (UC) | |
| E1. Ulcerative proctitis | 1 (1.9) |
| E2. Left sided UC | 30 (56.6) |
| E3. Pancolitis | 22 (41.5) |
| IBD severity | |
| Mild to moderate | 51 (41.5) |
| Severe | 72 (58.5) |
| EIMs | 28 (22.8) |
| Aphthous stomatitis | 20 (16.3) |
| Arthritis | 25 (20.3) |
| Primary sclerosing cholangitis | 2 (1.6) |
| Erythema nodosum | 3 (2.4) |
| Medications | |
| Mesalamine | 42 (34.1) |
| Azathioprine | 44 (35.8) |
| Methotrexate | 3 (2.4) |
| Adalimumab | 32 (26) |
| Infliximab | 21 (17.1) |
| Surgery | |
| Colectomy | 8 (6.5) |
| Small bowel resection | 6 (4.9) |
| Pouch surgery | 2 (1.6) |
SD – Standard deviation; CD – Crohn’s disease; IBD – Inflammatory bowel disease; UC – Ulcerative colitis; EIMs – Extraintestinal manifestations